TY - JOUR
T1 - A mouse model of pulmonary Mycobacteroides abscessus infection
AU - Maggioncalda, Emily C.
AU - Story-Roller, Elizabeth
AU - Mylius, Julian
AU - Illei, Peter
AU - Basaraba, Randall J.
AU - Lamichhane, Gyanu
N1 - Funding Information:
This work was supported by the Cystic Fibrosis Foundation grant LAMICH17GO and NIH R21 award AI137720 to GL. NIH-NIAID R01AI106733 and TBRU-U19AI111224 to RJB. ECM was supported by the NIH F31 award HL147392 and ESR was supported by the NIH T32 award AI007291. We would like to thank Dr. Nicole Ammerman and Dr. Eric Nuermberger of Johns Hopkins University for participating in meetings to discuss these studies. We would also like to thank Dr. Kiera Cohen, Johns Hopkins University, for reviewing this manuscript.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - There is no preclinical mouse model to investigate pulmonary Mycobacteroides abscessus (formerly Mycobacterium abscessus) infection in an immunocompetent mouse strain, especially in the context of antibiotic testing and regimen development. We developed a mouse model of pulmonary M. abscessus infection using the aerosolized route of infection that leads to an increase in bacterial burden post- implantation and develops pathology as a result. In this mouse model, treatment with corticosteroid allows for initial proliferation and sustained M. abscessus pulmonary infection and permits evaluation of efficacies of antibiotics. Administration of corticosteroids that permitted higher levels of bacterial burden in the lungs were more likely to have pathology. Treatment of mice with antibiotics administered intranasally or subcutaneously significantly reduced lung M. abscessus burden. In addition to the reference strain, independent clinical isolates of M. abscessus also readily establish infection and proliferate in the lungs of mice in this model.
AB - There is no preclinical mouse model to investigate pulmonary Mycobacteroides abscessus (formerly Mycobacterium abscessus) infection in an immunocompetent mouse strain, especially in the context of antibiotic testing and regimen development. We developed a mouse model of pulmonary M. abscessus infection using the aerosolized route of infection that leads to an increase in bacterial burden post- implantation and develops pathology as a result. In this mouse model, treatment with corticosteroid allows for initial proliferation and sustained M. abscessus pulmonary infection and permits evaluation of efficacies of antibiotics. Administration of corticosteroids that permitted higher levels of bacterial burden in the lungs were more likely to have pathology. Treatment of mice with antibiotics administered intranasally or subcutaneously significantly reduced lung M. abscessus burden. In addition to the reference strain, independent clinical isolates of M. abscessus also readily establish infection and proliferate in the lungs of mice in this model.
UR - http://www.scopus.com/inward/record.url?scp=85081008628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081008628&partnerID=8YFLogxK
U2 - 10.1038/s41598-020-60452-1
DO - 10.1038/s41598-020-60452-1
M3 - Article
C2 - 32111900
AN - SCOPUS:85081008628
SN - 2045-2322
VL - 10
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 3690
ER -